The Failure Patterns of Nasopharygeal Carcinoma After Intensity-Modulated Radiotherapy and Implications for Surveillance

References

• Lee AW, Ng WT, Chan YH, Sze H, Chan C, Lam TH. The battle against nasopharyngeal cancer. Radiother Oncol. 2012;104(3):272–278. doi:10.1016/j.radonc.2012.08.001
   PubMed Web of Science ®Google Scholar
• Chen YP, Chan A, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi:10.1016/S0140-6736(19)30956-0
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Pfister D. NCCN clinical practice guidelines in oncology: head and neck cancers. Version1; 2020: 88–89.
   Google Scholar
• Chan A, Felip E. Nasopharyngeal cancer: eSMOclinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:123–125. doi:10.1093/annonc/mdp150
   PubMed Web of Science ®Google Scholar
• Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014;110(3):398–403. doi:10.1016/j.radonc.2013.10.020
   PubMed Web of Science ®Google Scholar
• Au KH, Ngan RK, Ng AW, et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: a report of 3328 patients (HKNPCSG 1301 study). Oral Oncol. 2018;77:16–21. doi:10.1016/j.oraloncology.2017.12.004
   PubMed Web of Science ®Google Scholar
• Tian YM, Liu MZ, Zeng L, et al. Long-term outcome and pattern of failure for patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. Head Neck. 2019;41(5):1246–1252. doi:10.1002/hed.25545
   PubMed Web of Science ®Google Scholar
• Felice D, Vincentiis D, Valentini V, et al. Follow-up program in head and neck cancer. Crit Rev Oncol Hematol. 2017;113:151–155. doi:10.1016/j.critrevonc.2017.03.012
   PubMed Web of Science ®Google Scholar
• Zhou GQ, Lv JW, Tang LL, et al. Evaluation of the National Comprehensive Cancer Network and European Society for Medical Oncology nasopharyngeal carcinoma surveillance guidelines. Front Oncol. 2020;10:119. doi:10.3389/fonc.2020.00119
   PubMed Web of Science ®Google Scholar
• Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. 8th ed. NewYork, NY: Springer International Publishing; 2017:19.
   Google Scholar
• Ollier E, Blanchard P, Le Teuff G, et al. Penalized Poisson model for network meta-analysis of individual patient time-to-event data. Stat Med. 2022;41(2):340–355. doi:10.1002/sim.9240
   PubMed Web of Science ®Google Scholar
• Lee AW, Sze WM, Au JSK, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005;61(4):1107–1116. doi:10.1016/j.ijrobp.2004.07.702
   PubMed Web of Science ®Google Scholar
• Lin S, Pan J, Han L, et al. Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin. Radiother Oncol. 2014;110(3):385–389. doi:10.1016/j.radonc.2014.01.011
   PubMed Web of Science ®Google Scholar
• Lee AW, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992;23(2):261–270. doi:10.1016/0360-3016(92)90740-9
   PubMed Web of Science ®Google Scholar
• Gou X, Duan B, Shi H, et al. The relations of dosimetric parameters with long-term outcomes and late toxicities in advanced T-stage nasopharyngeal carcinoma with IMRT. Head Neck. 2020;42(1):85–92. doi:10.1002/hed.25986
   PubMed Web of Science ®Google Scholar
• Ng W, Lee MCH, Chang ATY, et al. The impact of dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRT. Oral Oncol. 2014;50(5):506–512. doi:10.1016/j.oraloncology.2014.01.017
   PubMed Web of Science ®Google Scholar
• Tian YM, Xiao WW, Bai L, et al. Impact of primary tumor volume and location on the prognosis of patients with locally recurrent nasopharyngeal carcinoma. Chin J Cancer. 2015;34(6):247–253. doi:10.1186/s40880-015-0019-5
   PubMedGoogle Scholar
• Bagri PK, Singhal MK, Singh D, et al. Diagnosis of post-radiotherapy local failures in nasopharyngeal carcinoma: a prospective institutional study. Iran J Cancer Prev. 2014;7(1):35–39.
   PubMedGoogle Scholar
• Chong VF, Fan YF. Detection of recurrent nasopharyngeal carcinoma: MR imaging versus CT. Radiology. 1997;202(2):463–470. doi:10.1148/radiology.202.2.9015075
   PubMed Web of Science ®Google Scholar
• Liu T, Xu W, Yan WL, et al. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiother Oncol. 2007;85(3):463–470. doi:10.1016/j.radonc.2007.11.002
   PubMed Web of Science ®Google Scholar
• Lan M, Huang Y, Chen C-Y, et al. Prognostic value of cervical nodal necrosis in nasopharyngeal carcinoma: analysis if 1800 patients with positive cervical nodal metastasis at MR imaging. Radiology. 2015;276(2):536–544. doi:10.1148/radiol.15141251
   PubMed Web of Science ®Google Scholar
• Batsakis JG. Nerves and neurotropic carcinomas. Ann Otol Rhinol Laryngol. 1985;94(4 Pt 1):426–427.
   PubMed Web of Science ®Google Scholar
• Liu L, Liang S, Li L, et al. Prognostic impact of magnetic resonance imaging-detected cranial nerve involvement in nasopharyngeal carcinoma. Cancer. 2009;115(9):1995–2003. doi:10.1002/cncr.24201
   PubMed Web of Science ®Google Scholar
• Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16(4):1310–1317. doi:10.1200/JCO.1998.16.4.1310
   PubMed Web of Science ®Google Scholar
• Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16(6):645–655. doi:10.1016/S1470-2045(15)70126-9
   PubMed Web of Science ®Google Scholar
• Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–1520. doi:10.1016/S1470-2045(16)30410-7
   PubMed Web of Science ®Google Scholar
• Ou D, Blanchard P, Khoury C, et al. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. Oral Oncol. 2016;62:114–121. doi:10.1016/j.oraloncology.2016.10.011
   PubMed Web of Science ®Google Scholar
• Twu CW, Wang W-Y, Chen -C-C, et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys. 2014;89(1):21–29. doi:10.1016/j.ijrobp.2014.01.052
   PubMed Web of Science ®Google Scholar
• Chen YP, Liu X, Zhou Q, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021;398(10297):303–313. doi:10.1016/S0140-6736(21)01123-5
   PubMed Web of Science ®Google Scholar
• Leung SF, Chan KC, Ma BB, et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol. 2014;25(6):1204–1208. doi:10.1093/annonc/mdu117
   PubMed Web of Science ®Google Scholar